Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders.
Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis.
Inflammatory cortical demyelination in early multiple sclerosis.
Gordon Research Conference on Myelin Biology and Pathobiology of Myelinating Glia
Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.
Foxp3(+) Treg cells in the inflamed CNS are insensitive to IL-6-driven IL-17 production.
Keystone Symposium: Multiple Sclerosis
The relation between inflammation and neurodegeneration in multiple sclerosis brains.
Are natural killer cells involved in multiple sclerosis etiology? Evidences from NKp46/NCR1 receptor modulation in an observational study.
Effect of 4-aminopyridine on vision in multiple sclerosis patients with optic neuropathy.
Long-term use of glatiramer acetate by 11 pregnant women with multiple sclerosis: a retrospective, multicentre case series.
Treatments for relapsing-remitting multiple sclerosis: summarising current information by network meta-analysis.
Teva Pharmaceutical Industries Limited's CEO Discusses Q1 2012 Results - Earnings Call Transcript
Interferon in relapsing-remitting multiple sclerosis.
Top ten research priorities for spinal cord injury: the methodology and results of a British priority setting partnership.
Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a ...
Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis: A Randomized Clinical Trial.
Dilantin
Cladribine interferes with IL-1β synaptic effects in experimental multiple sclerosis.
Dimethyl fumarate selectively reduces memory T cells in multiple sclerosis patients.
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab.
FTY720 impairs CD8 T-cell function independently of the sphingosine-1-phosphate pathway.
A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis.

Pages